Yüklüyor......
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agn...
Kaydedildi:
| Yayımlandı: | J Immunother Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5950135/ https://ncbi.nlm.nih.gov/pubmed/29754585 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0342-x |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|